Recombinant Human E3 ubiquitin-protein ligase RNF167 (RNF167)

What is the molecular structure of RNF167?

RNF167 is a type I transmembrane protein containing four key structural elements: a signal peptide, a central membrane-spanning region, a C-terminal RING domain, and two N-terminal glycosylation sites at positions N33 and N79 . Bioinformatic analyses predict a molecular weight of 38 kDa, though glycosylation causes the protein to migrate as a diffuse band at a higher molecular weight on SDS-PAGE . Experimental evidence confirms these glycosylation sites through endoglycosydase H and peptide-N-glycosydase F (PNGaseF) treatments, which result in sharper, lower molecular mass bands . Additionally, site-directed mutagenesis creating N33Q and N79Q mutations demonstrates shifts in protein mobility consistent with the predicted glycosylation pattern .

Where is RNF167 localized within cells?

RNF167 exhibits a distinct subcellular distribution pattern with predominantly lysosomal localization. Colocalization studies using fluorescence microscopy have revealed that:

• RNF167 shows minimal overlap with early endosome marker Rab5

• It partially colocalizes with late endosomal markers Rab7 and Rab9

• It demonstrates extensive colocalization with lysosomal membrane proteins Lamp-1 in HeLa cells and Lamp-2 in hippocampal neurons

• Importantly, cell surface biotinylation assays have identified a significant fraction of RNF167 expressed at the plasma membrane of neurons, suggesting dual localization

This distribution pattern positions RNF167 to regulate both lysosomal protein degradation and surface protein ubiquitination, particularly for membrane receptors like AMPA receptors.

What are the known tissue expression patterns of RNF167?

PCR-based gene expression analysis using a human multiple tissue cDNA panel has demonstrated ubiquitous expression of RNF167 across tissues, but with notable variations in expression levels . The highest expression levels are observed in the liver, pancreas, and testis, with comparatively lower expression in brain tissue . Within the brain, RNF167 protein is expressed at similar levels in the cortex and hippocampus, as confirmed by immunoblotting with specific RNF167 antibodies . This expression pattern suggests tissue-specific roles for RNF167 that may extend beyond its characterized neuronal functions.

What are the most effective methods for studying RNF167 protein interactions?

Several complementary approaches have proven effective for characterizing RNF167 interactions:

• In vitro autoubiquitination assays - These have successfully demonstrated functional interactions between RNF167 and multiple E2 enzymes, including UBE2D1 and UBE2N . The methodology involves incubating purified RNF167 with specific E2 enzymes, ubiquitin, and ATP, followed by detection of ubiquitination products.

• Binding assays with kinetic analysis - Direct binding studies have revealed submicromolar dissociation constants between RNF167 and selected E2 enzymes . These typically employ surface plasmon resonance or isothermal titration calorimetry.

• Computational modeling - Models of interaction between the RING domain of RNF167 and conjugating enzymes provide structural insights into these protein-protein interactions .

• Co-immunoprecipitation assays - Particularly useful for detecting interactions in cell lysates, these have confirmed binding between RNF167 and its E2 partners as well as substrate proteins .

• Fluorescence microscopy - This approach has effectively demonstrated colocalization of RNF167 with E2 enzymes in endosomes and lysosomes, confirming where these interactions occur within cells .

How can researchers effectively manipulate RNF167 activity in experimental systems?

Several validated approaches can be employed to modulate RNF167 activity:

• RING domain mutation - Creating mutations in the RING domain effectively disrupts E3 ligase activity while maintaining protein expression, serving as a dominant-negative form . This approach has successfully demonstrated increased AMPAR surface expression in hippocampal neurons.

• RNA interference - Specific shRNAs targeting RNF167 have been validated for knockdown experiments in neuronal systems . This method resulted in increased surface and total expression of AMPAR subunits.

• Lentiviral expression systems - These enable efficient delivery of wild-type or mutant RNF167 constructs to primary neurons and organotypic slice cultures .

• E2 enzyme inhibition - Pharmacological inhibition of specific E2 partners, such as UBE2N, has been shown to diminish substrate ubiquitination (e.g., AMPA-induced GluA2 ubiquitination in hippocampal neurons) .

• Biolistic transfection - For electrophysiological studies, this approach has enabled simultaneous comparison of synaptic currents between RNF167-manipulated and control cells in hippocampal slice cultures .

How does RNF167 contribute to AMPA receptor regulation in neurons?

RNF167 functions as a critical regulator of AMPA receptor (AMPAR) trafficking and synaptic strength through several mechanisms:

• Activity-dependent ubiquitination: RNF167 mediates the ubiquitination of GluA2 AMPAR subunits, particularly following increased synaptic activity induced by bicuculline treatment . This post-translational modification serves as a signal for receptor internalization.

• Surface expression control: Expression of dominant-negative RNF167 (RING mutant) significantly increases GluA2 surface expression in hippocampal neurons (133.5 ± 7.9% compared to 100.0 ± 3.9% in control cultures) . Similarly, RNF167 knockdown increases surface expression of both GluA1 and GluA2 subunits .

• Synaptic strength regulation: Electrophysiological recordings demonstrate that mutant RNF167 expression increases evoked AMPAR EPSC amplitude by 77% at Schaffer collateral/CA1 synapses, while NMDAR EPSCs remain unaffected . This confirms RNF167's selective regulation of AMPAR-mediated neurotransmission.

• E2 enzyme cooperation: The polyubiquitination of GluA2 requires cooperation between RNF167 and specific E2 enzymes, particularly UBE2N, which can only polyubiquitinate GluA2 after initial ubiquitin priming by another E2 enzyme .

These findings position RNF167 as a key molecular switch in controlling synaptic strength through the selective regulation of AMPAR surface expression and stability.

What is the mechanism of RNF167 interaction with E2 ubiquitin-conjugating enzymes?

RNF167 demonstrates a complex pattern of interactions with multiple E2 ubiquitin-conjugating enzymes:

• Functional cooperation: In vitro studies have established that RNF167 functionally interacts with multiple E2 enzymes, with particular importance for UBE2D1 and UBE2N in the context of AMPAR ubiquitination .

• Binding kinetics: Kinetic analyses reveal submicromolar dissociation constants between RNF167 and selected E2 enzymes, indicating relatively high-affinity interactions .

• Sequential ubiquitination process: For GluA2 polyubiquitination, a sequential mechanism has been identified wherein an initiating E2 enzyme first primes the substrate with ubiquitin, followed by UBE2N-mediated polyubiquitin chain extension . This two-step process is essential for effective substrate modification.

• Cellular localization of interactions: Fluorescence microscopy has confirmed that these RNF167-E2 interactions occur primarily in endosomes and lysosomes, consistent with RNF167's predominant subcellular localization .

• Structural basis: Computational modeling of the interaction between the RING domain of RNF167 and various E2 enzymes has provided insights into the structural determinants of these interactions .

What role does RNF167 play in the regulation of RIG-I-like receptors (RLRs) in antiviral immunity?

Recent research (2025) has identified RNF167 as a critical regulator of RIG-I-like receptors (RLRs), which are essential for type I interferon (IFN-I) activation during antiviral responses . Key findings include:

• Dual degradation pathways: RNF167 appears capable of directing substrates for degradation through both proteasomal and lysosomal pathways simultaneously . This represents an atypical form of ubiquitylation that may serve as a fail-safe mechanism for ensuring effective regulation of immune signaling.

• Immune homeostasis maintenance: By regulating the stability and activity of RLRs, RNF167 helps maintain immune homeostasis while allowing appropriate antiviral responses .

• E3 ligase functionality: As with AMPAR regulation, RNF167's E3 ubiquitin ligase activity is central to its ability to modify RLRs with ubiquitin chains that signal for degradation .

This newly identified function positions RNF167 at the interface between cellular metabolism, protein quality control, and innate immune regulation.

How can recombinant RNF167 be effectively produced and purified for biochemical studies?

Based on established protocols for E3 ubiquitin ligases, the following approach is recommended:

• Expression system selection: Bacterial systems (E. coli) are suitable for producing the RING domain alone, while eukaryotic systems (insect cells, mammalian cells) are preferred for full-length RNF167 to ensure proper folding and post-translational modifications, particularly glycosylation .

• Solubility considerations: Due to its transmembrane domain, full-length RNF167 presents solubility challenges. Consider using:

  • Detergent solubilization (e.g., CHAPS, DDM)

  • Truncated constructs lacking the transmembrane domain

  • Fusion with solubility tags (MBP, SUMO)

• Purification strategy: A typical workflow includes:

  • Affinity chromatography (His-tag or GST-tag)

  • Ion exchange chromatography

  • Size exclusion chromatography

• Activity validation: Purified recombinant RNF167 should be validated through:

  • Auto-ubiquitination assays with various E2 enzymes

  • Substrate ubiquitination assays using purified GluA2 C-terminal domains

  • Binding assays with known interactors

• Storage considerations: The protein should be stored in buffer containing glycerol (10-20%) at -80°C, with avoidance of repeated freeze-thaw cycles.

What experimental approaches are most effective for studying RNF167's role in synaptic plasticity?

Several complementary approaches have proven effective:

• Electrophysiological recordings in manipulated systems: Dual whole-cell recordings from organotypic hippocampal slice cultures with biolistic transfection of wild-type or mutant RNF167 provide direct measurement of synaptic strength changes . This approach allows simultaneous comparison of transfected and control neurons.

• Confocal imaging of surface receptors: Antibody-based confocal imaging assays using non-permeabilized neurons enable quantification of AMPAR surface expression following RNF167 manipulation .

• Activity-dependent ubiquitination assays: Treatment of neuronal cultures with bicuculline to induce synaptic activity, followed by immunoprecipitation and ubiquitin detection, reveals RNF167's role in activity-dependent receptor modification .

• Paired-pulse facilitation measurements: These assess presynaptic function to differentiate between pre- and post-synaptic effects of RNF167 manipulation .

• FACS-based surface expression assays: These provide quantitative measurement of receptor surface levels in large populations of manipulated cells .

• Long-term potentiation/depression paradigms: Although not explicitly described in the provided studies, these approaches would be valuable for assessing RNF167's role in synaptic plasticity.

How does RNF167 function integrate with other ubiquitin ligases in cellular protein quality control?

RNF167 operates within a complex network of E3 ubiquitin ligases that collectively regulate protein trafficking, quality control, and degradation:

• Distinct subcellular localization: Unlike many E3 ligases that function primarily in the cytosol or nucleus, RNF167's predominant localization in lysosomes and endosomes, with a smaller population at the plasma membrane, gives it a specialized role in the endolysosomal pathway .

• Substrate specificity: While other E3 ligases like Nedd4-1 also regulate AMPAR trafficking, RNF167 appears to have distinct activity profiles and responses to neuronal activity .

• E2 enzyme preferences: RNF167 demonstrates functional interactions with multiple E2 enzymes, including UBE2D1 and UBE2N, suggesting it may serve as a hub for different ubiquitination patterns depending on which E2 is recruited .

• Dual degradation pathways: Recent evidence suggests RNF167 can direct substrates for degradation through both proteasomal and lysosomal pathways simultaneously, a relatively unusual capability that places it at the intersection of major cellular degradation systems .

What are the most promising directions for future research on RNF167?

Based on current knowledge gaps and emerging findings, several research directions appear particularly promising:

• Structural studies: Obtaining high-resolution structures of RNF167 in complex with E2 enzymes and/or substrates would provide crucial insights into its mechanism of action and substrate recognition.

• Systems biology approaches: Comprehensive identification of the RNF167 "ubiquitome" through proteomics approaches would reveal the full range of its cellular substrates beyond AMPARs and RLRs.

• Regulatory mechanisms: Investigation of how RNF167 activity itself is regulated (through post-translational modifications, protein-protein interactions, or subcellular localization changes) represents an important unexplored area.

• Neural circuit implications: Given RNF167's role in synaptic strength regulation, examining its contribution to learning, memory, and neurological disorders at the circuit level would connect molecular mechanisms to behavior.

• Therapeutic targeting: Developing small molecules that modulate RNF167 activity could have applications in neurological disorders characterized by glutamatergic dysfunction or in viral infections where RLR regulation is dysregulated.

• Comparative analysis: Investigating how RNF167 function differs across tissues, particularly comparing its high-expressing tissues (liver, pancreas, testis) with the brain, would reveal tissue-specific roles and regulation.

What are the methodological challenges in studying post-translational modifications mediated by RNF167?

Several technical challenges complicate the study of RNF167-mediated ubiquitination:

• Ubiquitination site identification: Determining precise ubiquitination sites on substrates requires mass spectrometry approaches optimized for detecting ubiquitin remnants after tryptic digestion. This is particularly challenging for membrane proteins like AMPARs.

• Ubiquitin chain topology analysis: Different ubiquitin chain linkages (K48, K63, etc.) signal for different cellular fates. Distinguishing these requires specialized ubiquitin mutants and linkage-specific antibodies.

• Temporal dynamics: Ubiquitination is often a transient modification, particularly for signaling rather than degradation. Capturing these events requires careful timing and possibly deubiquitinase inhibitors.

• Subcellular resolution: Given RNF167's multiple locations (plasma membrane, endosomes, lysosomes), determining where specific ubiquitination events occur requires sophisticated fractionation or imaging approaches.

• E2 cooperation mechanisms: Understanding how multiple E2 enzymes sequentially cooperate with RNF167 requires reconstituted systems with purified components and careful order-of-addition experiments.